Apogee Therapeutics, Inc. Common Stock Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2023
2022
-75M
-84M
0M
6M
-3M
6M
-274M
0M
315M
0M
-0 %
0M
0M
-274M
118M
-34M
152M
-75M
-16M
-40M
0M
2M
11M
10M
0M
0M
168M
0M
-0 %
0M
0M
0M
152M
152M
0M
-16M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
-30M
-32M
0M
2M
-3M
3M
-40M
0M
0M
0M
-0 %
0M
0M
-274M
118M
-70M
188M
-30M
-20M
-21M
0M
2M
0M
0M
0M
0M
317M
0M
-0 %
0M
0M
2M
188M
63M
125M
-20M
-15M
-19M
0M
1M
0M
3M
0M
0M
-2M
0M
-0 %
0M
0M
-2M
125M
-16M
141M
-15M
-11M
-13M
0M
1M
0M
1M
0M
0M
-2M
0M
-0 %
0M
0M
-2M
141M
-11M
152M
-11M
-9M
-14M
0M
2M
1M
2M
0M
0M
158M
0M
-0 %
0M
0M
168M
152M
149M
3M
-9M
-7M
-20M
0M
0M
9M
3M
0M
0M
5M
0M
-0 %
0M
0M
0M
-2M
-2M
152M
-7M
-15M
-2M
0M
0M
0M
0M
0M
0M
0M
0M
0 %
0M
0M
-2M
152M
0M
0M
0M
-15M
0M
0M
0M
0M
0M
0M
0M
0M
0M
0 %
0M
0M
-2M
0M
0M
0M
0M